Septerna, Inc.
Septerna develops oral small molecule GPCR modulators for endocrinology, immunology, inflammation, and metabolic diseases using its Native Complex Platform.
SCHEDULE 13G/ANov 16Latest SEC filing
Nov 9Latest story
Septerna develops oral small molecule GPCR modulators for endocrinology, immunology, inflammation, and metabolic diseases using its Native Complex Platform.
November 2026
August 2026